Alcoholic Liver Disease

Efficacy and safety study of GS-4997 with prednisolone vs. prednisolone alone in adults with severe alcoholic hepatitis

Enrollment status: Actively enrolling

Primary objective

To evaluate the efficacy and safety of GS-4997 (selonsertib) administered with prednisolone vs. prednisolone alone in patients diagnosed with severe alcoholic hepatitis (AH) over the 26-week study period. There remains a large unmet medical need for alternative therapies to prednisolone treatment alone in AH patients.

Main inclusion criteria

Main exclusion criteria

Contacts for referrals or questions:

Principal investigator: Robert Fontana, MD,